Coverage
Filings
Orion's collaboration partner Bayer announced U.S. FDA approval for darolutamide, an androgen receptor inhibitor (ARi), for metastatic hormone-sensitive prostate cancer (mHSPC).
| 6 Sept 2016 |
| Orion Corporation: Announcement of transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons | 31 Aug 2016 |
| Orion Corporation: Announcement of transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons | 30 Aug 2016 |
| Orion Corporation: Announcement of transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons | 11 Aug 2016 |
| Orion Corporation: Announcement of transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons | 9 Aug 2016 |
| Orion Corporation: Announcement of transactions with shares and linked securities in Orion Corporation made by managers and their closely associated persons | 8 Aug 2016 |